In Vitro Anticancer Activity of cis-Diammineplatinum(II) Complexes with β-Diketonate Leaving Group Ligands
Name
Lippard_In vitro anticancer.pdf
Size
1.94 MB
Format
Adobe PDF
Checksum (MD5)
c0262e9c6ed47faf958cbb80342b7347
Author(s)
Wilson, Justin J.
Lippard, Stephen J.
Date Issued
May 2012
Journal
Journal of Medicinal Chemistry
Publisher
American Chemical Society (ACS)
Citation
Wilson, Justin J., and Stephen J. Lippard. “In Vitro Anticancer Activity of cis-Diammineplatinum(II) Complexes with β-Diketonate Leaving Group Ligands.” Journal of Medicinal Chemistry 55, no. 11 (June 14, 2012): 5326-5336.
Version
Author's final manuscript
Abstract
Five cationic platinum(II) complexes of general formula, [Pt(NH[subscript 3])[subscript 2](β-diketonate)]X are reported, where X is a noncoordinating anion and β-diketonate = acetylacetonate (acac), 1,1,1,-trifluoroacetylacetonate (tfac), benzoylacetonate (bzac), 4,4,4-trifluorobenzoylacetonate (tfbz), or dibenzoylmethide (dbm), corresponding, respectively, to complexes 1–5. The log P values and the stabilities of 1–5 in aqueous solution were evaluated. The phenyl ring substituents of 3–5 increase the lipophilicity of the resulting complexes, whereas the trifluoromethyl groups of 2 and 4 decrease the stability of the complexes in aqueous solution. The uptake of 1–5 in HeLa cells increases as the lipophilicity of the investigated complex increases. Cancer cell cytotoxicity studies indicate that 1 and 3 are the least active complexes whereas 2, 4, and 5 are comparable in activity to cisplatin.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1021/jm3002857
